Market By Therapeutic Application, Product, Analysis Purpose, End-user, Analysis Platform, Biomarker Type, Clinical Application And Geography | Forecast 2019-2027
According to Triton, the liquid biopsy market in Latin America is expected to proliferate with a CAGR of 26.60% in the forecast period of 2019-2027.
The countries that have been considered in the report on Latin America’s liquid biopsy market are:
• Brazil
• Mexico
• Rest of Latin America
A trend that is related to precision medicine is the emergence of tissue/tumour-agnostic drugs, which target specific genetic variants within cancer and drive the use of liquid biopsy diagnostics for detecting these variations. The expanded approval of Merck’s drug, Keytruda in May 2017 for use in patients with metastatic cancer and those who have microsatellite instability or mismatch repair deficiency was the first instance of this phenomenon. Other drug companies are now pursuing the same approval strategy, which emphasizes the genetic feature of cancer rather than the organ of origin.
Report scope can be customized per your requirements. Request For Customization
However, the absence of reimbursement can abridge the adoption of liquid biopsy. The reimbursement & treatment monitoring for liquid biopsy is insufficient, and few laboratories perform these procedures. The average cost of liquid biopsy is around $925, and the reimbursement provided for it is around $300-$435. The reimbursement coverage depends on the type of cancer, early or late screening procedure and the type of therapy selected for it. A liquid biopsy is a new technology in the market, which is highly adopted in developed countries. However, in developing countries, though there is an immense market opportunity, this technology is not much adopted. In developing countries, a tissue biopsy is mostly preferred than liquid biopsy. In such countries, the companies and laboratories need to convince the physicians about the liquid biopsy. Further, lack of reimbursement and awareness about liquid biopsy can decline its adoption, which can impact the market growth negatively.
B. Braun Melsungen AG is a leading healthcare company that supplies products for intensive care, anaesthesia, cardiology, surgery and extracorporeal blood treatment. It also offers healthcare services to general practitioners, hospitals and the homecare sector. B. Braun operates in the Asia-Pacific, the Middle East, Africa, Europe, Latin America and North America. The company’s comprehensive product & service portfolio is providing it with a leadership position in the market. B. Braun’s presence in diverse markets helps it reduce its dependency risk. Strategic acquisitions are likely to help the company expand its footprint in the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1.
LATIN AMERICA LIQUID BIOPSY MARKET - SUMMARY
2.
INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1.
THREAT OF NEW ENTRANTS
2.3.2.
THREAT OF SUBSTITUTES
2.3.3.
BARGAINING POWER OF BUYERS
2.3.4.
BARGAINING POWER OF SUPPLIERS
2.3.5.
THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1.
CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2.
DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3.
TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4.
RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1.
HIGH COST OF TEST
2.9.2.
LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10.
MARKET OPPORTUNITIES
2.10.1.
ADVANCEMENT IN TECHNOLOGY
2.10.2.
RISING NUMBER OF CANCER PATIENTS
2.11.
MARKET CHALLENGES
2.11.1.
LACK OF REIMBURSEMENT
2.11.2.
SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3.
LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4.
LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6.
LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8.
LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9.
LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1.
LATIN AMERICA
10.2.
COUNTRY ANALYSIS
10.2.1.1.
BRAZIL
10.2.1.2.
MEXICO
10.2.1.3.
REST OF LATIN AMERICA
11. COMPETITIVE LANDSCAPE
11.1.
AGILENT TECHNOLOGIES, INC.
11.2.
BOSTON SCIENTIFIC CORPORATION
11.3.
ARGON MEDICAL DEVICES, INC.
11.4.
B. BRAUN MELSUNGEN AG
11.5.
CINTEC MEDICAL LTD.
11.6.
ROCHE DIAGNOSTICS CORPORATION
11.7.
AD-TECH MEDICAL INSTRUMENT CORP.
11.8.
I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9.
QIAGEN N.V.
11.10.
BECTON, DICKINSON
11.11.
PLANMECA OY
11.12.
BIO-RAD LABORATORIES, INC.
11.13.
CARDINAL HEALTH, INC.
11.14.
COOK MEDICAL, INC.
11.15.
FISCHER MEDICAL TECHNOLOGIES LLC
11.16.
C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1.
RESEARCH SCOPE & DELIVERABLES
12.1.1.
OBJECTIVES OF STUDY
12.1.2.
SCOPE OF STUDY
12.2.
SOURCES OF DATA
12.2.1.
PRIMARY DATA SOURCES
12.2.2.
SECONDARY DATA SOURCES
12.3.
RESEARCH METHODOLOGY
12.3.1.
EVALUATION OF PROPOSED MARKET
12.3.2.
IDENTIFICATION OF DATA SOURCES
12.3.3.
ASSESSMENT OF MARKET DETERMINANTS
12.3.4.
DATA COLLECTION
12.3.5.
DATA VALIDATION & ANALYSIS
TABLE 1 LATIN AMERICA LIQUID
BIOPSY MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY
BIOMARKER CLASSES
TABLE 3 LATIN AMERICA LIQUID
BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 LATIN AMERICA LIQUID
BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 LATIN AMERICA LIQUID
BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 LATIN AMERICA LIQUID
BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 LATIN AMERICA LIQUID
BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF
DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR
INDUSTRIES
TABLE 10 LATIN AMERICA LIQUID
BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 LATIN AMERICA LIQUID
BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 LATIN AMERICA BIOPSY
MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE 1 LATIN AMERICA LIQUID
BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 LATIN AMERICA LIQUID
BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 LATIN AMERICA LIQUID
BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST
CANCER
FIGURE 5 LATIN AMERICA LIQUID
BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 LATIN AMERICA LIQUID
BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 LATIN AMERICA LIQUID
BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 LATIN AMERICA LIQUID
BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 LATIN AMERICA LIQUID
BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 LATIN AMERICA LIQUID
BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 LATIN AMERICA LIQUID
BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 LATIN AMERICA LIQUID
BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 LATIN AMERICA LIQUID
BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 LATIN AMERICA LIQUID
BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 LATIN AMERICA LIQUID
BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 LATIN AMERICA LIQUID
BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 LATIN AMERICA LIQUID BIOPSY
MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 LATIN AMERICA LIQUID
BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 LATIN AMERICA LIQUID
BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 LATIN AMERICA LIQUID
BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 LATIN AMERICA LIQUID
BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 LATIN AMERICA LIQUID
BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 LATIN AMERICA LIQUID
BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 LATIN AMERICA LIQUID
BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 LATIN AMERICA LIQUID
BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 LATIN AMERICA LIQUID
BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 LATIN AMERICA LIQUID
BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 LATIN AMERICA LIQUID
BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 LATIN AMERICA LIQUID
BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 LATIN AMERICA LIQUID
BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 LATIN AMERICA LIQUID
BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 LATIN AMERICA LIQUID
BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 LATIN AMERICA LIQUID
BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 LATIN AMERICA LIQUID
BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 BRAZIL LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 36 MEXICO LIQUID BIOPSY
MARKET 2019-2027 ($ MILLION)
FIGURE 37 REST OF LATIN AMERICA
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)